Fig. 8From: Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritisIncidence of adverse events per organ system in the comparison of selective COX-2 inhibitors versus placebo in patients with ankylosing spondylitis: meta-analysis of three randomized clinical trials. Subtitle: 1) Celecoxib 400 mg vs placebo. (2) Celecoxib 200 mg vs placebo. (3) Etoricoxib 90 mg vs placebo. (4) Celecoxib 400 mg vs placebo. (5) Celecoxib 200 mg vs placebo. (6) Etoricoxib 90 mg vs placebo. (7) Celecoxib 400 mg vs placebo. (8) Celecoxib 200 mg vs placebo. (9) Etoricoxib 90 mg vs placebo. (10) Celecoxib 400 mg vs placebo. (11) Celecoxib 200 mg vs placeboBack to article page